Medical abortion is increasingly heralded as an ideal method for decreasing maternal mortality in health-care resource-deprived areas and as an answer to the shrinking pool of physicians willing to perform abortions. The advent of progesterone receptor modulators (PRMs) and the recent approval by the Food and Drug Administration of ella (ulipristal) as an emergency contraceptive put pharmacists in the center of abortion controversy. Pharmacists, worldwide, need to be aware of the controversy surrounding the introduction of PRMs. particularly with regard to the effect on health policy, their mechanism of action, associated adverse events, and common off-label uses. Once understood, genuine opportunity exists for pharmacists to serve a fundamental role in positively shaping public health policy.
BlanchardK, ShochetT, CoyajiK, NgoeT, WinikoffB. Misoprostol alone for early abortion: an evaluation of seven potential regimens. Contraception2005; 72:91–7.
2.
AttardiB, BurgensonJ, HildS, ReelJ. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol2004; 88:277–88.
3.
SpitzI, BardinC, BentonL, RobbinsA. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med1998; 338:1241–7.
American Association of Pro Life Obstetricians and Gynecologists, Christian Medical Association and Concerned Women for America.Citizen petition re: request for stay and repeal of the approval of Mifeprex (mifepristone) for the medical termination of intrauterine pregnancy through 49 days' gestation. Filed FDA, August2002. www.cwfa.org/ru486/CitizenPetition_Mifeprex8.20.02.pdf (accessed 2010 Oct 30).
6.
GaryMM, HarrisonDJ. Analysis of severe adverse events related to the use of mifepristone as an abortifacient. Ann Pharmacother2006; 40:191–7. DOI 10.1345/aph.1G481
7.
FischerM, BhatnagarJ, GuarnerJ. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N Engl J Med2005; 353:2352–60.
8.
MiechR. Pathophysiology of mifepristone-induced septic shock due to Clostridium sordellii. Ann Pharmacother2005; 39:1483–8. DOI 10.1345/aph.1G189
9.
MiechR. Pathopharmacology of excessive hemorrhage in mifepristone abortions. Ann Pharmacother2007; 41:2002–7. DOI 10.1345/aph.1K351
ICH M3 (R2): Guideline on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals (current Step 4 ver., June 11, 2009): sec. 11.3 (“Women of Childbearing Potential”). www.fda.gov/RegulatoryInformation/Guidances/ucm129520.htm (accessed 2010 Sept 25).
13.
TeutschG, PhilibertD. History and perspectives of antiprogestins from the chemist's point of view. Hum Reprod1994; 9(suppl 1):12–31.
14.
TarantalAF, HendrickxAG, MatlinSA. Effects of two antiprogestins on early pregnancy in the long-tailed macaque (Macaca fascicularis). Contraception1996; 54:107–15.
15.
FinePT, MatheH, GindeS, CullinsV, MorfesisJ. Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception. Obstet Gynecol2010; 115(2 Pt 1):257–63.
16.
GlasierAF, CameronST, FinePM. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet2010; 375:555–62. DOI 10.1016/S0140-6736(10)60101-8
17.
CreininM, SchlaffW, ArcherD. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol2006; 108:1089–97.
18.
Food and Drug Administration.Medical officer's addendum. Study #9728: Plan B OTC label comprehension study. sNDA-21–045. Rockville, MD: Food and Drug Administration.
World Health Organization.National-level monitoring of the achievement of universal access to reproductive health: conceptual and practical considerations and related indicators—report of a WHO/UNFPA technical consultation. Geneva, Switzerland, March 13-15, 2007. ISBN 978-92-4-159683-1, p21.
